National Methadone Conference AMTA 2001 Tuesday, October 9th 2 P.M. Administrative Detox: Necessary Use or Abuse Joe Neuberger, Delaware NAMA James DePasquale, Long Beach Patient Committee This roundtable examined the practice of “administrative detoxification” from programs, and explored the conflicts between what programs often perceive as a necessary evil and patients often perceive as a…

DOJ publishes guidance on Opioid Use Disorder and the Americans with Disabilities Act April 15, 2022 “The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (Ada), which…

Herman Joseph, PhD 1931 – 2019 May 28, 2019 May 6, 2019 Dr. Joseph was one of the important influences on addiction and criminal justice during the latter 20th and early 21st century.  For more than 50 years he has worked as a social research scientist in the interrelated fields of addiction, treatment, criminal justice,…

Down for reformatting

National Alliance of Methadone Advocates 435 Second Avenue New York, NY 10010 Phone: (212) 595-6262 Review Guidelines for the Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office Section I Preamble Paragraph 2 The second sentence should also include the fact that Medical Maintenance has been demonstrated to…

FDA Talk Paper April 20, 2001 T01-15 Print Media: 301-827-6242 Broadcast Media: 301-827-3434 Consumer Inquiries: 888-INFO-FDA The FDA is strengthening warnings to physicians about serious cardiac adverse events associated with Orlaam (levomethadyl acetate HC), a drug for opiate addiction treatment. FDA has changed the Orlaam labeling to increase the strength of the warnings and to…